Sunday 18 October 2026
Export SSKN’s income statement to Excel — free account
Strata Skin Sciences, Inc.
SSKN Healthcare Medical Devices
Strata Skin Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.7 million, down 8.54% from fiscal 2024. In the quarter to December 2025, revenue fell 2.97%, EPS grew 111.5%, free cash flow fell 376.9% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow SSKN
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.19 | 0.30 | 0.29 | 0.33 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.52) | (144.24) | (4.92) | (20.02) | |
P/B ratio |
2.02 | 7.03 | 31.01 | 4.13 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.87 | 0.56 | 0.59 | 0.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.57) | (9.43) | (9.22) | 42.54 | |
EV/FCF |
(6.27) | (4.97) | (6.89) | (28.15) | |
Quick Ratio |
0.45 | 0.70 | 0.71 | 0.85 | |
Current Ratio |
0.58 | 0.95 | 0.98 | 1.05 | |
Net Debt/EBITDA |
4.49 | (45.24) | (10.57) | (11.01) | |
Debt/Assets |
50.29% | 49.84% | 49.70% | 44.45% | |
Debt/Equity |
5.28 | 11.65 | 49.58 | 5.71 | |
Asset Turnover |
0.94 | 0.87 | 0.93 | 0.90 | |
Operating CF/Net income |
(0.85) | 0.04 | 0.78 | 0.23 | |
Capex/Depreciation |
(0.33) | (1.03) | 0.05 | (0.15) | |
Interest Coverage |
1.47 | (2.36) | (4.53) | (4.15) | |
Research and Development Expense of Revenue |
0.72% | 2.48% | 1.12% | 1.41% | |
Selling, General and Administrative Expense of Revenue |
58.29% | 84.70% | 84.09% | 81.71% | |
Intangible Assets out of Total Assets |
0.16 | 0.18 | 0.23 | 0.22 | |
Share Based Compensation of Revenue |
1.87% | 3.06% | 1.67% | 1.89% | |
Graham Net Nets |
(2.05) | (1.64) | (1.74) | (1.43) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(111.90%) | (129.61%) | (124.02%) | (85.98%) | |
Free Cash Flow Yield |
(72.73%) | (38.04%) | (29.25%) | (6.07%) | |
Revenue per Share |
2.00 | 1.55 | 1.84 | 1.63 | |
Operating CF per Share |
(0.05) | (0.01) | (0.47) | (0.13) | |
Capex per Share |
(0.07) | (0.23) | 0.01 | (0.05) | |
Free Cash Flow per Share |
(0.12) | (0.24) | (0.45) | (0.18) | |
Cash per Share |
1.70 | 1.58 | 1.43 | 1.88 | |
Shareholders Equity per Share |
0.63 | 0.29 | 0.07 | 0.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.63 | 0.29 | 0.07 | 0.64 | |
Free Cash Flow |
(0.55) | (1.08) | (1.88) | (0.75) | |
Working Capital |
(11.14) | (0.76) | (0.23) | 0.74 | |
Capital Expenditures |
(0.31) | (1.02) | 0.06 | (0.20) | |
Net Current Asset Value |
(12.01) | (15.13) | (16.64) | (15.72) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.15 | (0.01) | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.69 | 3.97 | 4.00 | 4.32 | |
Average Payables |
2.60 | 2.35 | 2.92 | 3.20 | |
Average Inventory |
2.53 | 2.90 | 2.96 | 2.68 | |
Average Assets |
32.72 | 35.46 | 35.15 | 37.16 | |
Average Common Equity |
3.94 | 5.33 | 4.90 | 6.05 |
Columns are period end dates